Baseline characteristics of participants
| . | Women who stopped using CHCs (n = 66) . | Controls (n = 28) . |
|---|---|---|
| Age, y, n (%) | 27.2 (6.5) | 30.9 (8.5) |
| Weight, kg, mean (SD) | 64 (12.6) | 61.5 (9.0) |
| BMI (kg/m2), mean (SD) | 23.2 (4.5) | 22.3 (3.1) |
| White race, n (%) | 60 (90.9%) | 26 (92.6%) |
| Currently smoking, n (%) | 11 (16.7%) | 5 (17.9%) |
| Family history of VTE, n (%) | 3 (4.5%) | 3 (10.7%) |
| Contraception type | ||
| Combined oral contraceptive, n (%) | 55 (83.3%) | — |
| Transcutaneous patch, n (%) | 1 (1.5%) | — |
| Vaginal ring, n (%) | 10 (15.2%) | — |
| Nonhormonal IUD, n (%) | — | 10 (35.7%) |
| Progestogen-only pill/implant/IUD, n (%) | — | 6 (21.4%) |
| None or condom, n (%) | — | 12 (42.9%) |
| Progestogen type (CHC)∗ | ||
| Second generation, n (%) | 36 (54.6%) | — |
| Third generation, n (%) | 7 (10.6%) | — |
| Other CHCs, n (%) | 23 (34.8%) | — |
| Mean duration of contraception use, y, mean (SD) | 5.1 (5.0) |
| . | Women who stopped using CHCs (n = 66) . | Controls (n = 28) . |
|---|---|---|
| Age, y, n (%) | 27.2 (6.5) | 30.9 (8.5) |
| Weight, kg, mean (SD) | 64 (12.6) | 61.5 (9.0) |
| BMI (kg/m2), mean (SD) | 23.2 (4.5) | 22.3 (3.1) |
| White race, n (%) | 60 (90.9%) | 26 (92.6%) |
| Currently smoking, n (%) | 11 (16.7%) | 5 (17.9%) |
| Family history of VTE, n (%) | 3 (4.5%) | 3 (10.7%) |
| Contraception type | ||
| Combined oral contraceptive, n (%) | 55 (83.3%) | — |
| Transcutaneous patch, n (%) | 1 (1.5%) | — |
| Vaginal ring, n (%) | 10 (15.2%) | — |
| Nonhormonal IUD, n (%) | — | 10 (35.7%) |
| Progestogen-only pill/implant/IUD, n (%) | — | 6 (21.4%) |
| None or condom, n (%) | — | 12 (42.9%) |
| Progestogen type (CHC)∗ | ||
| Second generation, n (%) | 36 (54.6%) | — |
| Third generation, n (%) | 7 (10.6%) | — |
| Other CHCs, n (%) | 23 (34.8%) | — |
| Mean duration of contraception use, y, mean (SD) | 5.1 (5.0) |
There were no missing data of participants’ characteristics.
Categories explained in ”Methods.”